Pinedo-Villanueva, Rafael
Charokopou, Mata
Toth, Emese
Donnelly, Kerry
Cooper, Cyrus
Prieto-Alhambra, Daniel
Libanati, Cesar
Javaid, Muhammad K.
Article History
Received: 3 January 2019
Accepted: 23 January 2019
First Online: 2 February 2019
Compliance with ethical standards
:
: The concept for this paper arose from a meeting that was funded by UCB Pharma, with no further funding provided. M Charokopou, E Toth, K Donnelly and C Libanati are employees of UCB. Outside of the submitted work: MK Javaid has received research grants and speaker honorarium from UCB, Lilly UK and Amgen and stock options for Zebra Medical Vision; R Pinedo-Villanueva has been co-applicant in research grants from Amgen; C Cooper has received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB; D Prieto-Alhambra has received research grants from Servier, Amgen and UCB and his department has received speaker and consultancy fees from Amgen and UCB respectively.
Free to read: This content has been made available to all.